Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes.
about
Convergence of the tuberculosis and diabetes epidemics: renewal of old acquaintancesImpact of diabetes mellitus on treatment outcomes of patients with active tuberculosisConvergence of a diabetes mellitus, protein energy malnutrition, and TB epidemic: the neglected elderly populationA review of co-morbidity between infectious and chronic disease in Sub Saharan Africa: TB and Diabetes Mellitus, HIV and Metabolic Syndrome, and the impact of globalizationUse of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerationsDiabetes Mellitus as Hub for Tuberculosis Infection: A SnapshotUnderstanding and applying pharmacometric modelling and simulation in clinical practice and researchSystematic drug repositioning based on clinical side-effectsPredictors of Prolonged TB Treatment in a Dutch Outpatient SettingDefining a research agenda to address the converging epidemics of tuberculosis and diabetes. Part 1: Epidemiology and clinical management.Early interventions for diabetes related tuberculosis associate with hastened sputum microbiological clearance in Virginia, USA.Dosing of antibacterial agents in obese adults: does one size fit all?Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.Understanding pharmacokinetics to improve tuberculosis treatment outcome.Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA.Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA.Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis.Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetesDiabetes mellitus and the risk of multidrug resistant tuberculosis: a meta-analysis.Type 2 diabetes and multidrug-resistant tuberculosisTuberculosis and diabetes mellitus: convergence of two epidemics.A prospective, observational study of adverse reactions to drug regimen for multi-drug resistant pulmonary tuberculosis in central India.Tuberculosis and diabetes mellitus - an underappreciated association.Impact of diabetes mellitus on clinical parameters and treatment outcomes of newly diagnosed pulmonary tuberculosis patients in ThailandEffects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patientsImpact of diabetes on the natural history of tuberculosis.Diabetes is a strong predictor of mortality during tuberculosis treatment: a prospective cohort study among tuberculosis patients from Mwanza, Tanzania.Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.Increased risk of tuberculosis among foreign-born persons with diabetes in California, 2010-2012.Clinical management of concurrent diabetes and tuberculosis and the implications for patient servicesExposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients.Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people.Rifampin resistance and diabetes mellitus in a cross-sectional study of adult patients in rural South India.Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIVTreatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar.Clinical Pharmacokinetics of Rifampin in Patients with Tuberculosis and Type 2 Diabetes Mellitus: Association with Biochemical and Immunological Parameters.Diabetes mellitus is associated with increased mortality during tuberculosis treatment: a prospective cohort study among tuberculosis patients in South-Eastern Amahra Region, Ethiopia.Mycobacterial clearance from sputum is delayed during the first phase of treatment in patients with diabetes.
P2860
Q22242955-C9A0ECFA-3720-4032-BFBC-41BB07273FCDQ24648013-F27D8AC2-203A-44AE-88F3-05589128479BQ26741699-3388C3EB-68CF-409C-91B4-40A07A749A94Q27498795-9036B512-3D2E-4946-B8AB-C478F16A97F6Q28072205-5F4EF65D-0521-4E7E-A258-31F5A4CCF141Q28077839-28695131-6F4C-4B4C-A7B7-B746381974CEQ28468334-3AEDEE8E-A703-4233-9D07-0414B4383A23Q28478506-A5DF6B96-C3EE-453A-93CC-FF2DD2C07929Q28553471-743B390B-F082-4308-9B27-B2D98A249CC1Q30234699-CDF71D8A-8CA5-491C-9DAE-1FAA89D2CCA7Q30274831-98C893FB-BA9E-4F01-AA71-A1A0B97CEEFAQ30362353-39D28F07-620A-4E6C-9929-77D2FC18F9A4Q30383012-B9FFA94D-8681-47BD-AFC9-A6B18C5EF62AQ30411703-6F100B62-4795-4B17-B1E1-4837C289C7E2Q30415746-D5EFAAB5-E429-45A0-B898-D60E8EBBF273Q30427912-24026E5A-2C8B-4547-A2B4-D9211BA8CA23Q30834393-28E0F9F4-77A5-4D7F-B26A-E4CC237732BFQ33282527-D4F8B534-9D33-4AAE-8305-0BF6B1DC0E0EQ33291134-30703700-4AB3-47F1-907F-063A9DE07A77Q33521011-F7248A5D-9C6A-47C0-9A54-2668E310C287Q33682812-48F149FB-5867-4789-B410-081B27F2C620Q33920693-9A0F7E7B-463D-470F-8244-35220C4BC104Q34156234-9B2C81BC-F0BD-441A-A4DF-31BE85FC8287Q34194183-89CABCD2-3CCC-4065-AC9A-F37A9C5B54B6Q34466787-0EB087B1-E167-4701-B3BA-29EA7F1CEF64Q34512578-06811E8E-B42C-4053-96C2-87DE5156CB5FQ34597564-C061C8A1-EF99-4A22-8893-959E5986AB34Q34663669-886EEB4E-3B0A-4A73-A334-23D6B2CEA0FAQ34707827-D4F3CFB2-5789-448E-8352-62A24CD845D1Q34729493-13430108-20D7-430B-AE14-E1A7792B771FQ35238051-59DE6517-D0E8-4255-BBC0-9AE6093662E7Q35240921-41658819-0358-4EB3-BB0C-CF0DF28E6B3FQ35584822-A5BF497D-A9B0-4A9B-A0F2-6948F148A562Q35806375-C184B928-F0F9-43FB-8110-28FA248129DBQ35819438-9C1268A1-1741-46E7-A983-0E61362B25AEQ35941434-63C8CBAB-6E37-49C0-8C20-F8F42C181E1FQ36268159-B9495643-9279-4735-A47D-59F9642D8E5EQ36290609-560D537B-4D34-4886-93F7-32F03255D7A9Q36725344-3ADB6B62-DEC4-4E22-9C7E-F736D3DA2423Q36802743-911CF91F-AF9C-4613-A2BF-DFC9130EFB26
P2860
Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Exposure to rifampicin is stro ...... erculosis and type 2 diabetes.
@ast
Exposure to rifampicin is stro ...... erculosis and type 2 diabetes.
@en
Exposure to rifampicin is stro ...... erculosis and type 2 diabetes.
@nl
type
label
Exposure to rifampicin is stro ...... erculosis and type 2 diabetes.
@ast
Exposure to rifampicin is stro ...... erculosis and type 2 diabetes.
@en
Exposure to rifampicin is stro ...... erculosis and type 2 diabetes.
@nl
prefLabel
Exposure to rifampicin is stro ...... erculosis and type 2 diabetes.
@ast
Exposure to rifampicin is stro ...... erculosis and type 2 diabetes.
@en
Exposure to rifampicin is stro ...... erculosis and type 2 diabetes.
@nl
P2093
P2860
P921
P356
P1476
Exposure to rifampicin is stro ...... erculosis and type 2 diabetes.
@en
P2093
Andre J A M van der Ven
Erni J Nelwan
Halim Danusantoso
Hanneke M J Nijland
Janneke E Stalenhoef
Rob E Aarnoutse
Ron H H Nelwan
Rovina Ruslami
P2860
P304
P356
10.1086/507543
P407
P577
2006-08-22T00:00:00Z